Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bloomage BioTechnologySHSE:688363 +0.56%94 Return-on-Tangible-Asset is 4.34% as of Jun. 2026, which is 67% below its 10-year median of 13.10. GuruFocus rates SHSE:688363 with a GF Score™ of 94/100 and a GF Value™ of ¥39.03 (Fairly Valued). The stock has 8 warning signs investors should review. Among 1,618 Chemicals companies, Bloomage BioTechnology ranks worse than 56.74% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Bloomage BioTechnology's annualizedNet Income for the quarter that ended in Jun. 2026 was ¥353 Mil. Bloomage BioTechnology's average total tangible assets for the quarter that ended in Jun. 2026 was ¥8,129 Mil. Therefore, Bloomage BioTechnology's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 4.34%.
The historical rank and industry rank for Bloomage BioTechnology's Return-on-Tangible-Asset or its related term are showing as below:
SHSE:688363'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 2.22 Med: 13.1 Max: 23.84
Current: 2.81
During the past 10 years, Bloomage BioTechnology's highest Return-on-Tangible-Asset was 23.84%. The lowest was 2.22%. And the median was 13.10%.
SHSE:688363's Return-on-Tangible-Asset is ranked worse than 56.74% of 1618
companies
in the Chemicals industry
Industry Median: 3.625
vs SHSE:688363: 2.81
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Bloomage BioTechnology Return-on-Tangible-Asset Related Terms
Bloomage BioTechnology Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Bloomage BioTechnology's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688363 vs LIN, SHW, ECL: Return-on-Tangible-Asset Comparison
For the Specialty Chemicals subindustry, Bloomage BioTechnology's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bloomage BioTechnology Return-on-Tangible-Asset vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Bloomage BioTechnology's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Bloomage BioTechnology's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 4.34% mean?
Bloomage BioTechnology (SHSE:688363) has a Return-on-Tangible-Asset of 4.34% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Bloomage BioTechnology and its competitors. This is 67% below median its historical median of 13.10. Over the past decade, Bloomage BioTechnology's Return-on-Tangible-Asset has ranged from 2.22 to 23.84. According to the industry distribution chart, Bloomage BioTechnology ranks #918 out of 1618 companies in the Chemicals industry, placing it in the top 56.7%.
Is Bloomage BioTechnology's Return-on-Tangible-Asset too high?
Bloomage BioTechnology's current Return-on-Tangible-Asset of 4.34% is 67% below median its 10-year median of 13.10. Over the past 10 years, this metric has ranged from a low of 2.22 to a high of 23.84. The Chemicals industry median Return-on-Tangible-Asset is 3.63. Bloomage BioTechnology's value of 4.34% is 19.7% above this industry median. Based on the distribution chart, Bloomage BioTechnology ranks #918 out of 1618 companies in the Chemicals industry, which is below the industry midpoint. Overall, Bloomage BioTechnology has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bloomage BioTechnology's Return-on-Tangible-Asset compare to LIN and SHW?
According to the Chemicals industry distribution chart, Bloomage BioTechnology ranks #918 out of 1618 companies for Return-on-Tangible-Asset. This places Bloomage BioTechnology in the lower half of its industry. The industry median Return-on-Tangible-Asset is 3.63. Bloomage BioTechnology's value of 4.34% is 19.7% above this benchmark. Historically, Bloomage BioTechnology's own Return-on-Tangible-Asset has ranged from 2.22 to 23.84 over the past decade. While the company's 10-year median is 13.10 vs. the industry median of 3.63, Bloomage BioTechnology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Chemicals company?
The median Return-on-Tangible-Asset among Chemicals companies is 3.63, based on 1,618 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bloomage BioTechnology's current Return-on-Tangible-Asset of 4.34% is 19.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Bloomage BioTechnology and its competitors. For the Chemicals industry, the median Return-on-Tangible-Asset is 3.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bloomage BioTechnology's current Return-on-Tangible-Asset is 4.34%, which is 67% below median its own 10-year median of 13.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bloomage BioTechnology stock overvalued right now?
Based on GuruFocus' analysis, Bloomage BioTechnology (SHSE:688363) is currently considered Fairly Valued. The stock's GF Value™ is ¥39.03, compared to a current price of ¥36.15 — trading 7.4% below its estimated fair value. The current Return-on-Tangible-Asset is 4.34%, which is 67% below median its 10-year median of 13.10 and 19.7% above the Chemicals industry median of 3.63. Bloomage BioTechnology's overall GF Score™ is 94/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Bloomage BioTechnology (SHSE:688363), the current Return-on-Tangible-Asset is 4.34% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bloomage BioTechnology (SHSE:688363) Overvalued in 2026?
Based on GuruFocus' analysis, Bloomage BioTechnology stock appears to be undervalued.
The current stock price of ¥36.15 is trading 7.4% below its estimated GF Value™ of ¥39.03.
GuruFocus considers Bloomage BioTechnology to be Fairly Valued.
Key valuation signals for SHSE:688363:
Return-on-Tangible-Asset: 4.34% (67% below median its 10-year median of 13.10)
GF Value™: ¥39.03 vs. price of ¥36.15 (7.4% below fair value)
Industry Position: 19.7% above the Chemicals median (#918 of 1618)
No single metric tells the full story. See the SHSE:688363 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bloomage BioTechnology Corp Ltd manufactures and sells a variety of chemicals and chemical-based products, typically made from hyaluronic acid or sodium hyaluronic acid. The company's products include raw materials, medical products, functional skincare, and functional foods. Raw materials, mainly hyaluronic acid, are used in pharmaceuticals, medical devices, cosmetics, and food. Medical products span beauty and therapeutic uses, such as viscoelastics, lubricants, fillers, and skin protectors. Skincare items include lotions, creams, and masks, while functional foods feature hyaluronic acid drinks and supplements.
94GF Score
Get the complete analysis for SHSE:688363
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688363 has been successfully added to your 
